A Study to Evaluate How Tamsulosin (at 1 Dose) and Solifenacin (at 2 Different Doses) Are Taken up From the Intestine, Distributed Through the Body and Eliminated From the Body When Administered in Combination as a Single Tablet (Called EC905)

Healthy Subjects Clinical Trial

Official title:
An Open-label, Randomized, Two-way Crossover, Multiple Dose Study to Evaluate the Steady State Pharmacokinetics of the Two Final Combination Tablet Formulations (EC905; Tamsulosin HCl/ Solifenacin Succinate; 0.4 mg/6 mg and 0.4 mg/9 mg) in Healthy Male Volunteers Over 45 Years of Age

Status Completed

Clinical Trial Summary

Tamsulosin (sold under the name Omnic OCAS) is used for treatment of voiding complaints related to an enlarged prostate. Solifenacin (sold under the name Vesicare) is used for the treatment of patients suffering from problems related to overactive bladder, such as needing to go to the toilet frequently and often having a sudden urgent need to go to the toilet. Certain patients with an enlarged prostate have complaints that may benefit from a combination of tamsulosin and solifenacin. EC905 is a single tablet containing both tamsulosin and solifenacin. The current study aims at investigating how tamsulosin and solifenacin are taken up from the intestine, distributed through the body and eventually eliminated from the body when taken as a single EC905 tablet.

Clinical Trial Description

In this study there are two sequence groups with 27 subjects in total. In Period 1, subjects are randomized to receive one of the two final combination tablet formulations of tamsulosin HCl and solifenacin succinate. In Period 1, 13 subjects receive one combination and 14 subjects receive the other combination. In Period 2, the alternate treatment is provided.

Screening takes place from Days -21 to -2 before the first admission day (Day -1). EC905 is administered from Day 1 to Day 12 (treatment period 1), and from Day 13 to Day 24 (treatment period 2). All treatments are administered with subjects in the fasted state.

Blood samples for pharmacokinetic (PK) analysis of tamsulosin HCl and solifenacin free base are collected, and assessments of vital signs, safety electrocardiogram (ECG), safety laboratory, adverse events and concomitant medications are performed.

Subjects are discharged on day 25 and an End of Study Visit takes place at least 10 days after the second treatment period, or after withdrawal. ;

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01953848
Study type	Interventional
Source	Astellas Pharma Inc
Contact
Status	Completed
Phase	Phase 1
Start date	April 2010
Completion date	July 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05483998` - A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants	Phase 1
Recruiting	`NCT02417714` - Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Recruiting	`NCT02235012` - Cognitive Biases Under Ketamine	N/A
Completed	`NCT05088343` - Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects	Phase 1
Completed	`NCT04418973` - Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject.	N/A
Not yet recruiting	`NCT06248801` - Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets	Phase 1
Terminated	`NCT04068259` - Single Ascending Dose Study of PBI-4547 in Healthy Subjects	Phase 1
Completed	`NCT03279302` - Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects	Phase 1
Not yet recruiting	`NCT06233162` - Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets	Phase 1
Recruiting	`NCT04159844` - Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects	N/A
Completed	`NCT06137911` - Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults.	Phase 1
Completed	`NCT04849286` - Measurement of HTL0016878 in Cerebrospinal Fluid	Phase 1
Not yet recruiting	`NCT06233227` - Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule	Phase 1
Completed	`NCT04096157` - A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants	Phase 1
Completed	`NCT01200368` - Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants	Phase 3
Recruiting	`NCT05805033` - Peri-Implant Soft Tissue Integration in Humans: Influence of Material	N/A
Completed	`NCT04027803` - Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®	Phase 1
Recruiting	`NCT03467880` - Multicenter Study of Impulse Oscillometry in Chinese	N/A
Completed	`NCT02903095` - Single Ascending Dose Study of TD-1439 in Healthy Subjects	Phase 1
Active, not recruiting	`NCT02341508` - A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers	Phase 1